Keros Therapeutics (KROS) Earnings Date & Reports

Key Takeaways

• Revenue collapsed to $0.37 million in Q1 2026 from $211.25 million a year earlier, reflecting the cycling-off of one-time license revenue tied to the Takeda Pharmaceuticals partnership.
• Earnings per share (EPS) of -$1.21 missed the consensus analyst estimate of approximately -$1.02, as operating costs continued to outweigh partner-driven service revenue.
• Research and development (R&D) expenses fell 67% year over year to $16.1 million, underscoring the cost-savings impact of shifting elritercept-related development to Takeda.
• Cash and cash equivalents totaled $281.5 million as of March 31, 2026, a runway the company expects will fund operations into the first half of 2028.
• Shares dropped roughly 8% the day after the release, reflecting investor unease with the post-deal revenue reset and a wider-than-expected quarterly loss.

Earnings Context and Why It Matters

Keros Therapeutics (NASDAQ: KROS) entered 2026 in a fundamentally different financial position than the prior year. In 2025, the company recognized a $200 million upfront payment and a $10 million milestone under its exclusive license agreement with Takeda Pharmaceuticals for elritercept. Those one-time infusions distorted year-over-year comparisons, making Q1 2026 the first clean quarter reflecting Keros as a leaner, pipeline-focused biotech. Investors are now scrutinizing whether the company's reduced cost structure and advancing clinical programs — particularly rinvatercept for Duchenne muscular dystrophy (DMD) — can support the stock's long-term narrative amid shrinking reported revenues and ongoing net losses.

Reported Results

Keros reported total revenue of $0.37 million for the first quarter ended March 31, 2026, down from $211.25 million in the prior-year period. The figure consisted entirely of service and other revenue tied to transition services for Takeda, with no license revenue recognized during the quarter. This result fell well short of consensus analyst estimates, which had projected revenue of approximately $1.9 million.

Net loss attributable to common stockholders was $23.7 million, or -$1.21 per share on both a basic and diluted basis. That compares to net income of $148.5 million, or $3.62 per diluted share, in Q1 2025. The EPS result missed the consensus estimate, which ranged from approximately -$0.92 to -$1.04 depending on the source. The wider loss was primarily driven by the absence of high-margin license revenue rather than a meaningful increase in operating expenses.

On the cost side, R&D expenses dropped sharply to $16.1 million from $48.7 million a year earlier, reflecting the transition of elritercept-related development responsibilities to Takeda and the effects of a corporate restructuring completed in 2025. General and administrative (G&A) expenses edged down to $10.1 million from $10.5 million. Total operating expenses fell to $26.2 million from $59.2 million, demonstrating the leaner operating profile management had promised following the Takeda deal.

Cash and cash equivalents stood at $281.5 million as of March 31, 2026, compared to $287.4 million at year-end 2025. Management reiterated that the current cash position is expected to fund planned operating expenses and capital requirements into the first half of 2028.

AI Screener

For investors seeking to identify new opportunities across the biotechnology sector and beyond, Tickeron's AI Screener offers a powerful, AI-driven platform that scans thousands of stocks and exchange-traded funds (ETFs) using customizable filters. Users can sort the market by industry, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether tracking breakout candidates, trending stocks, or fundamentally screened ideas, the AI Screener helps traders and investors narrow the investable universe more efficiently than traditional manual screening methods. Explore the tool to see how AI-powered discovery can complement your market research process.

Market Reaction and Investor Sentiment

Keros shares declined approximately 8.3% in the trading session following the May 14 earnings release, moving from $11.99 to $10.99. The drop reflected a dual disappointment: the EPS miss and the stark revenue decline, even though the latter was widely anticipated given the non-recurring nature of the 2025 Takeda payment. Broader sentiment around the stock had already been under pressure — KROS had lost roughly 41% year to date as of the Q1 report, compared to an S&P 500 gain of about 8.8% over the same stretch. Analysts maintained a Moderate Buy consensus on the stock following the release, though several firms reduced their price targets, with the average target falling approximately 7.8% to around $21.20. The key debate among investors centers on whether the pipeline, led by rinvatercept, can generate sufficient catalysts to offset the absence of near-term product revenue.

Forward Outlook and Key Factors to Monitor

Looking ahead, Keros faces a critical period defined by clinical execution rather than financial engineering. The company expects to initiate a Phase 2 clinical trial of rinvatercept in patients with DMD during the second quarter of 2026. This represents the most significant near-term catalyst and will be closely watched for enrollment progress, trial design details, and any early safety or efficacy signals.

In parallel, management plans to engage regulators in the second half of 2026 on the design of a Phase 2 trial of rinvatercept in amyotrophic lateral sclerosis (ALS). Expanding into ALS would meaningfully broaden the addressable patient population and the drug's commercial potential, but regulatory feedback will be essential in shaping trial timelines and endpoints.

On the partnered side, Takeda is expected to advance elritercept into Phase 3 clinical trials for anemia in myelofibrosis. While Keros does not bear the development costs for this program, milestone payments and eventual royalties represent long-term upside that is not yet reflected in near-term revenue forecasts. Investors should monitor Takeda's public disclosures for updates on trial initiation and enrollment timelines.

Financially, the company's leaner operating structure provides a multi-year runway, reducing the risk of near-term dilution. However, quarterly revenue figures will likely remain modest and lumpy, driven by milestone timing and transition service fees rather than recurring product sales. Consensus estimates for Q2 2026 point to an EPS loss of approximately -$1.25 to -$1.34 on revenue of roughly $0.7 million to $0.8 million. Until Keros reaches commercialization — still several years away — pipeline progress, regulatory interactions, and cash management will remain the primary drivers of investor sentiment and stock performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations